Výsledky vyhledávání

Abstract P6-14-18: Updated Survival Analysis of a Phase III Study (EMBRACE) of Eribulin Mesylate Versus Treatment of Physician's Choice in Subjects with Locally Recurrent or Metastatic Breast Cancer Previously Treated with an Anthracycline and a Taxane

Autor: Jantien Wanders, J. Cortes, S. Seegobin, Chris Twelves, X Durando, D. Loesch, Joanne L. Blum, Linda T. Vahdat, K. Petrakova, C Akerele

Publikováno v: Cancer Research. 70:P6-14

Background: Eribulin mesylate (E7389) is a non-taxane microtubule dynamics inhibitor with a novel mode of action. EMBRACE was the first trial to compare overall survival (OS) of this new chemotherapeutic agent to real-life treatment choices (treatmen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ecc2a5275e282efc081cce35ce2e4c5c
https://doi.org/10.1158/0008-5472.sabcs10-p6-14-18

Zobrazit plný text záznamu

Abstract P6-13-02: Survival Outcomes with Eribulin Mesylate vs. Treatment of the Physician's Choice (TPC) in Heavily Pretreated Subjects with Locally Recurrent or Metastatic Breast Cancer in North America, Western Europe, and Australia: Results of the Phase III EMBRACE Study

Autor: Chris Twelves, S. Seegobin, C Akerele, Linda T. Vahdat, J. Cortes, Jantien Wanders

Publikováno v: Cancer Research. 70:P6-13

Background: Eribulin mesylate (E7389) is a nontaxane microtubule dynamics inhibitor. We conducted a randomized, controlled, open-label, phase III study to compare the efficacy and safety of eribulin vs. TPC in heavily pretreated subjects with locally

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c7a9e1c367e1fa51761aa07c93647105
https://doi.org/10.1158/0008-5472.sabcs10-p6-13-02

Zobrazit plný text záznamu

Abstract P6-13-01: Impact of the Number of Prior Chemotherapy Regimens on Overall Survival (OS) among Subjects with Locally Recurrent or Metastatic Breast Cancer Treated with Eribulin Mesylate: Results from the Phase III EMBRACE Study

Autor: J. Cortes, Joanne L. Blum, S. Seegobin, C Akerele, Chris Twelves, Jantien Wanders

Publikováno v: Cancer Research. 70:P6-13

Background: The randomized, controlled, open-label, phase III EMBRACE study compared the efficacy and safety of eribulin mesylate (E7389) vs. treatment of the physician's choice (TPC) in heavily pretreated subjects with late-stage breast cancer. The

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d49f6ce09011d685618aa88bd03344b6
https://doi.org/10.1158/0008-5472.sabcs10-p6-13-01

Zobrazit plný text záznamu

A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane

Autor: Jantien Wanders, Joanne L. Blum, Linda T. Vahdat, Chris Twelves, C Akerele, D. Loesch, Philippe Chollet, J. Cortes, S. Seegobin, K. Petrakova

Publikováno v: Journal of Clinical Oncology. 28:CRA1004-CRA1004

CRA1004^ Background: Eribulin mesylate (E7389; E) is a nontaxane microtubule dynamics inhibitor with a novel mode of action. This study is the first to compare overall survival (OS) with this new chemotherapeutic (CT) agent to real-life choices in he

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7926cfeae6f79709db1b15eb2975c9ab
https://doi.org/10.1200/jco.2010.28.18_suppl.cra1004

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání